Published in Ophthalmology on November 04, 2015
Does the use of acetylsalicylic acid have an influence on our vision? Clin Interv Aging (2016) 0.75
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91
Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina (1996) 2.27
Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med (2003) 2.00
Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol (1990) 1.83
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2012) 1.70
Massive hemorrhage complicating age-related macular degeneration. Clinicopathologic correlation and role of anticoagulants. Ophthalmology (1986) 1.44
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost (2009) 1.34
Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology (1991) 1.28
Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2000) 1.28
Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol (1995) 1.17
Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina (2010) 1.12
Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med (2003) 1.10
Spontaneous suprachoroidal haemorrhage in a patient with age-related macular degeneration on excessive anticoagulation therapy. Eye (Lond) (2002) 1.02
Massive intraocular hemorrhage associated with anticoagulation and age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (1988) 0.96
Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy. Am J Ophthalmol (2009) 0.92
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2014) 0.89
Macular degeneration: is aspirin a risk for progressive disease? JAMA (1991) 0.83
[Massive subretinal hemorrhage and anticoagulants. An unfortunate combination?]. Ophthalmologe (2012) 0.78
Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina (2013) 0.78
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 3.85
Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 1.45
Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol (2014) 1.20
Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2013) 1.07
Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. JAMA Ophthalmol (2016) 0.96
Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.94
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2014) 0.89
Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.88
Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology (2015) 0.86
Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2015) 0.85
Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2015) 0.84
Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. Ophthalmology (2014) 0.83
Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Am J Ophthalmol (2014) 0.82
Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology (2015) 0.82
Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Ophthalmology (2015) 0.82
The Practice Impact of Electronic Health Record System Implementation Within a Large Multispecialty Ophthalmic Practice. JAMA Ophthalmol (2015) 0.82
Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.78
Single-Nucleotide Polymorphisms Associated With Age-Related Macular Degeneration and Lesion Phenotypes in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol (2016) 0.76
Evaluating Effects of Switching Anti-Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema. JAMA Ophthalmol (2016) 0.76
Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology (2016) 0.75
Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents. JAMA Ophthalmol (2020) 0.75
Counterfeit Avastin in India: Punish the Criminals, Not the Patients. Am J Ophthalmol (2016) 0.75
The Use of a Mobile Van for School Vision Screening: Results of 63 841 Evaluations. Am J Ophthalmol (2015) 0.75